Amgen and Roche settle EPO dispute
This article was originally published in Scrip
The five-year US patent infringement dispute between Amgen and Roche concerning Amgen's patents on recombinant erythropoietin (EPO) has come to an end. Under a stipulation signed by both parties, a federal judge in Boston has entered final judgement and permanently enjoined Roche from infringing on Amgen's EPO patents. Roche has agreed to keep its pegylated erythropoietin product Mircera (continuous erythropoietin receptor activator; CERA) off the US market until mid-2014 as part of a limited licence agreement.